Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 8/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | GSK3B | P49841 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14120046 | 0.87 | PKM (0.51) | PKMMAPK1MEN1HPGDKMT2A | |
| SCHEMBL2436269 | 0.81 | PKM (0.47) | PKMMAPK1MEN1HPGDKMT2A | |
| SCHEMBL2441561 | 0.81 | PKM (0.47) | PKMMAPK1MEN1HPGDKMT2A | |
| SCHEMBL2436255 | 0.80 | MAPK1 (0.50) | PKMMAPK1MEN1HPGDKMT2A | |
| SCHEMBL2444983 | 0.80 | PKM (0.44) | PKMMAPK1MEN1HPGDKMT2A | |
| SCHEMBL2435765 | 0.78 | PKM (0.46) | PKMMAPK1MEN1HPGDKMT2A | |
| SCHEMBL2436439 | 0.78 | PKM (0.46) | PKMMAPK1MEN1HPGDKMT2A | |
| SCHEMBL2439533 | 0.76 | PKM (0.45) | PKMMAPK1MEN1HPGDKMT2A | |
| SCHEMBL2441230 | 0.76 | PKM (0.42) | PKMMAPK1MEN1HPGDKMT2A | |
| SCHEMBL2440866 | 0.76 | PKM (0.45) | PKMMAPK1MEN1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2539342-B1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-04-15 | — | — | EP | disclosed |
| US-8969376-B2 | Pyrazolopyrimidine compounds and their use as PDE10 inhibitors | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-03-03 | — | — | US | disclosed |
| EP-2539342-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | Mitsubishi Tanabe Pharma Corporation (JP) | 2013-01-02 | — | — | EP | disclosed |
| US-20120309754-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-12-06 | — | — | US | disclosed |
| WO-2011105628-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309754-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | PDE3B, PDE3A, PDE5A | PKM 296/4885MAPK1 286/4885CDK2 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.